ALK-Abelló A/S (OTCPK:AKBLF) Q2 2025 Earnings Conference Call August 21, 2025 7:30 AM ET
Company Participants
Claus Steensen Solje – Executive VP, CFO & Member of Management Board
Per Plotnikof – VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Peter Halling – President & CEO
Conference Call Participants
Benjamin Jackson – Jefferies LLC, Research Division
Jesper Ilsøe – DNB Carnegie, Research Division
Michael Novod – Nordea Markets, Research Division
Sushila Hernandez – Van Lanschot Kempen
Thomas Schultz Bowers – SEB, Research Division
Per Plotnikof
Hello, everyone, and welcome to this presentation of ALK’s Q2 results and the revised full year outlook. Thank you all for joining us. Let’s turn to Slide #2 with an intro to the agenda and the speakers.
My name is Per Plotnikof, I’m Head of Investor Relations. And with me today are CEO, Peter Halling; and CFO, Claus Steensen Solje. We will first be sharing a couple of highlights from Q2 followed by a closer look at market and product trends as well as half year financials. We will then provide an update on resources and on the pediatric agenda, our neffy partnership and other strategic priorities before we present the updated full year outlook.
As usual, we will end the presentation with a Q&A session. And to get started, I’ll hand over to Peter, Slide 3 for the highlights. Please go ahead, Peter.
Peter Halling
Thank you, Per, and thank you all for joining this call. Commercial execution of the key strategic initiatives, including the launches, was on top of our. These initiatives started contributing to sales growth in Q2, although they are still all in early stage. The initiatives have come on a good start and this bodes well for a capabilities. for children with House’s vitality is progressing well and have continued to exceed expectations.
Read the full article here
